(VIANEWS) – Genmab (GMAB), Air Lease Corporation (AL), InMode Ltd. (INMD) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Genmab (GMAB)
41.1% sales growth and 14.87% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.94.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 32.13. Meaning, the purchaser of the share is investing $32.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.87%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 2650% and 3720%, respectively.
Sales Growth
Genmab’s sales growth is negative 5% for the ongoing quarter and 41.1% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.1%, now sitting on 17.02B for the twelve trailing months.
Moving Average
Genmab’s worth is under its 50-day moving average of $31.88 and way below its 200-day moving average of $36.98.
2. Air Lease Corporation (AL)
13.9% sales growth and 7.99% return on equity
Air Lease Corporation, an aircraft leasing company, engages in the purchase and leasing of commercial jet transport aircraft to airlines worldwide. The company also sells aircraft from its operating lease portfolio to third parties, including other leasing companies, financial services companies, and airlines. In addition, it provides fleet management services to investors and owners of aircraft portfolios. As of December 31, 2019, the company owned a fleet of 275 aircraft, including 203 narrowbody jet aircraft and 89 widebody jet aircraft. Air Lease Corporation was founded in 2010 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, Air Lease Corporation has a trailing twelve months EPS of $4.46.
PE Ratio
Air Lease Corporation has a trailing twelve months price to earnings ratio of 8.7. Meaning, the purchaser of the share is investing $8.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.99%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Air Lease Corporation’s EBITDA is 9.08.
3. InMode Ltd. (INMD)
10.3% sales growth and 29.3% return on equity
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Earnings Per Share
As for profitability, InMode Ltd. has a trailing twelve months EPS of $2.1.
PE Ratio
InMode Ltd. has a trailing twelve months price to earnings ratio of 10.9. Meaning, the purchaser of the share is investing $10.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.3%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
InMode Ltd. ‘s EBITDA is 2.48.
Moving Average
InMode Ltd. ‘s value is below its 50-day moving average of $24.57 and way under its 200-day moving average of $33.57.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.6%, now sitting on 498.84M for the twelve trailing months.
4. Arcos Dorados Holdings (ARCO)
8.1% sales growth and 52.84% return on equity
Arcos Dorados Holdings Inc. operates as a franchisee of McDonald's restaurants. It has the exclusive right to own, operate, and grant franchises of McDonald's restaurants in 20 countries and territories in Latin America and the Caribbean, including Argentina, Aruba, Brazil, Chile, Colombia, Costa Rica, Curaçao, Ecuador, French Guiana, Guadeloupe, Martinique, Mexico, Panama, Peru, Puerto Rico, Trinidad and Tobago, Uruguay, the U.S. Virgin Islands of St. Croix and St. Thomas, and Venezuela. As of December 31, 2019, it operated or franchised 2,293 restaurants. Arcos Dorados Holdings Inc. was founded in 2007 and is based in Montevideo, Uruguay.
Earnings Per Share
As for profitability, Arcos Dorados Holdings has a trailing twelve months EPS of $0.86.
PE Ratio
Arcos Dorados Holdings has a trailing twelve months price to earnings ratio of 13.48. Meaning, the purchaser of the share is investing $13.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 52.84%.
Previous days news about Arcos Dorados Holdings(ARCO)
- According to Zacks on Monday, 11 December, "Arcos Dorados Holdings Inc. price-consensus-chart | Arcos Dorados Holdings Inc. Quote"
5. Fluor Corporation (FLR)
7.7% sales growth and 4.41% return on equity
Fluor Corporation provides engineering, procurement, and construction (EPC); fabrication and modularization; operation and maintenance; asset integrity; and project management services worldwide. It operates through four segments: Energy Solutions, Urban Solutions, Mission Solutions, and Other. The Energy Solutions provides solutions to the energy transition markets, including asset decarbonization, carbon capture, renewable fuels, waste-to-energy, green chemicals, hydrogen, nuclear power, and other low-carbon energy sources. It also provides consulting services, including feasibility studies, process assessments, and project finance structuring; and a range of services for small modular reactor technologies, as well as operation support services for nuclear power facilities and managing waste. This segment serves the oil, gas, and petrochemical industries. The Urban Solutions segment offers EPC and project management services to the infrastructure, advanced technologies, life sciences, and mining and metals industries. This segment also provides staffing services to the company and third-party clients with technical, professional, and craft resources on a contract or permanent placement basis. The Mission Solutions offers technical solutions to the U.S. and other governments. It also delivers solutions for nuclear security and operation, nuclear waste management, and laboratory management; and operation and maintenance, logistics, EPC, and life support solutions for mission-critical facilities across U.S. military service organizations. This segment offers site management, environmental remediation, and decommissioning for nuclear remediation at governmental facilities, as well as services to commercial nuclear clients. The Other segment researches, develops, licenses, and commercializes small modular nuclear reactor technology. It also provides unionized management and construction services. The company was founded in 1912 and is headquartered in Irving, Texas.
Earnings Per Share
As for profitability, Fluor Corporation has a trailing twelve months EPS of $0.71.
PE Ratio
Fluor Corporation has a trailing twelve months price to earnings ratio of 54.93. Meaning, the purchaser of the share is investing $54.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.41%.
Moving Average
Fluor Corporation’s worth is above its 50-day moving average of $36.13 and way above its 200-day moving average of $32.54.
Sales Growth
Fluor Corporation’s sales growth is 10.7% for the present quarter and 7.7% for the next.
Yearly Top and Bottom Value
Fluor Corporation’s stock is valued at $39.00 at 14:22 EST, under its 52-week high of $39.17 and way higher than its 52-week low of $25.69.
